Keeping Track: US FDA Clears Novel Flu Treatment Xofluza, Boosts Trintellix Label With Sexual Dysfunction Data
Executive SummaryThe latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Emerging Company Profile: Four-year-old Atriva Therapeutics GmbH is developing a drug to prevent the proliferation of flu virus by transiently inhibiting one of the patient’s own cellular processes, a host-mediated novel mechanism of action that could be effective against a range of respiratory virus infections.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.